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Thrombopoietin (TPO) and the TPO-receptor (TPO-R, or c-MPL) are
essential for hematopoietic stem cell (HSC) maintenance and
megakaryocyte differentiation. Agents that can modulate TPO-R
signaling are highly desirable for both basic research and clinical
utility. We developed a series of surrogate protein ligands for TPO-
R, in the form of diabodies (DBs), that homodimerize TPO-R on the
cell surface in geometries that are dictated by the DB receptor
binding epitope, in effect “tuning” downstream signaling re-
sponses. These surrogate ligands exhibit diverse pharmacological
properties, inducing graded signaling outputs, from full to partial
TPO agonism, thus decoupling the dual functions of TPO/TPO-R.
Using single-cell RNA sequencing and HSC self-renewal assays we
find that partial agonistic diabodies preserved the stem-like prop-
erties of cultured HSCs, but also blocked oncogenic colony forma-
tion in essential thrombocythemia (ET) through inverse agonism.
Our data suggest that dampening downstream TPO signaling is a
powerful approach not only for HSC preservation in culture, but
also for inhibiting oncogenic signaling through the TPO-R.
thrombopoietin signaling | megakaryopoiesis |
myeloproliferative neoplasm | hematopoietic stem cells
Since the landmark cloning of thrombopoietin (TPO) (1–4)and its receptor MPL (TPO-R) (5–7), there has been interest
in characterizing the role of the TPO/TPO-R interaction in
normal and pathological hematopoiesis. TPO signaling plays key
roles in regulating megakaryopoiesis and platelet production (8,
9) and in the support of hematopoietic stem cell (HSC) main-
tenance and self-renewal (10–16). Consequently, aberrant TPO/
TPO-R signaling can lead to severe hematological disorders,
including myeloproliferative neoplasms (MPNs) (17, 18) and bone
marrow failure syndromes (19, 20).
Despite initial hurdles with first generation recombinant throm-
bopoietin, which stimulated autoantibody formation resulting in
cytopenia, several second-generation peptide/small-molecule TPO
mimetics are now approved for immune thrombocytopenia and
hepatitis C-associated thrombocytopenia and bone marrow failure
syndromes (21). Side effects of TPO mimetics include thrombocy-
tosis, possibly thrombosis, bone marrow reticulin fibrosis, and re-
bound thrombocytopenia (22). Thus, fine tuning this therapeutically
important signaling axis remains an important goal.
TPO is a prototypical four-helix bundle cytokine (23) and
engages TPO-R using the canonical “growth hormone” mecha-
nistic and structural paradigm (24, 25). TPO dimerizes TPO-R
and induces downstream signaling through the JAK/STAT path-
way, principally activating JAK2 and STAT5 (26). However, the
few studies that have addressed how TPO-R dimerization dy-
namics and geometry, in response to TPO, relate to signaling
output (27), have hinted that TPO-R signaling could be manip-
ulated in therapeutically useful ways that are not exhibited by the
natural TPO ligand. This is important given that the activities of
the natural TPO molecule are clinically limited (28). Although
synthetic small molecule TPO-R agonists have been developed
(23), as well as agonist antibodies (29), they appear to phenocopy
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TPO-induced signaling and lack the element of fine control of
agonist output.
Two particularly relevant studies have hinted at the potential
promise of diversifying TPO pharmacology. In one study, the
authors showed that artificial chimeric TPO-R fusion proteins,
when forced into different symmetrical dimeric receptor orien-
tations, differentially promoted megakaryocyte differentiation,
cell adhesion, and myeloproliferative and myelodysplasia phe-
notypes in vivo (27). This intriguing result raised the possibility
that engineered ligands that could bind to unmodified TPO-R on
natural cells and alter dimer geometry, could potentially induce
different functional outcomes. Following this observation, we
demonstrated that a dimeric antibody format known as diabodies
(DBs), had the capacity to bind to different epitopes on the
EPO-R, a highly-related class I cytokine receptor, and induce
different dimerization geometries, modulating signal strength
(30). These DBs elicited a range of signaling pharmacology, from
full to partial agonism. Given that TPO-R and EPO-R both form
JAK2-associated homodimeric signaling complexes on the cell
surface and exhibit highly similar signaling signatures, these
studies motivated us to ask whether we could manipulate TPO-R
signaling with engineered surrogate ligands.
In the present study, we manipulate TPO-R signal strength,
borrowing a strategy commonly used for GPCRs that has been
rarely applied to cytokine receptors. We used DBs as “surrogate”
TPO-R ligands that bind to different epitopes on the TPO-R
extracellular domain (ECD), and as a result, alter the TPO-R
interdimer distance and geometry which results in a perturbed,
and fine-tuned, TPO-R downstream signal. We evaluated the
activities of these TPO-R DBs by measuring the level of TPO-R
dimerization and signaling downstream and exploring their ef-
fects on HSC gene expression and differentiation. We also
transcriptionally single-cell profiled the effects the DBs and TPO
had on proliferation and differentiation of fluorescence activated
cell sorting (FACS)-purified human HSCs after ex vivo expan-
sion (31, 32). In addition, the cytokine TPO is required in all cell
culture media to expand HSCs ex vivo for cell therapy (33).
Therefore, we evaluated whether substituting TPO with our
surrogate agonist TPO-R DBs could influence cell-fate decisions
and increase the HSC number for allogenic HSC transplanta-
tion. Several of the partial agonist TPO-R DB molecules control
HSC maintenance versus differentiation under ex vivo expansion
and differentiation conditions, thus pointing to tuning of TPO-R
signal strength as a major determinant of HSC homeostasis.
Collectively these studies show that DBs can split the dual
function of TPO/TPO-R (megakaryopoiesis and HSC mainte-
nance) and that the calibration and tuning of TPO-R can exert
differential effects on HSC fate decisions.
Results
Diabodies Induce Different Degrees of Agonistic Activity. As a proxy
for the natural TPO ligand, we used DBs, which have highly
engineerable scaffolds and the capacity to dimerize their targets
because they contain two binding sites. DBs are a dimeric, bi-
valent antibody format generated through a tandem arrange-
ment of two single-chain variable fragments (scFvs) connected by
a short linker. This format results in a dimeric molecule in which
the binding sites are closer together and more rigidly connected
than a typical IgG-like antibody where two Fabs are linked by an
Fc. The closer proximity of the two binding sites in the DBs
increases chances for productive TPO-R dimerization and sig-
naling. Previously, a full agonist DB against TPO-R was repor-
ted, showing that a DB can in principle dimerize TPO-R in a
productive signaling geometry (29). We generated three versions
of DBs using sequences of anti-TPO-R DBs, as described in SI
Appendix, Supplementary Materials and Methods (29, 30, 32).
Each of these DBs has different sequences of complementary
determining regions (CDR) loops, and therefore likely bind to
different epitopes on TPO-R, thus dimerizing TPO-R in differ-
ent geometries. Using yeast surface display of the TPO-R D1D2
domains, we found that AK111 appears to bind to an over-
lapping epitope where TPO binds, and can block TPO binding to
100%. AK119, on the other hand, appears to bind to a partially
overlapping epitope with TPO and AK111, and therefore TPO
and AK111 can only block AK119 binding by 50% (SI Appendix,
Fig. S1 A and B).
We then evaluated binding of the three DBs AK111, 113, and
119 to the TPO-R receptor ectodomain (SD1-2) displayed on the
surface of yeast, and found that all DBs bound with comparable
efficiencies to TPO-R (Fig. 1A), with DBs AK113 and AK111
binding having higher affinity. We next explored whether these
DBs were functional in inducing TPO-R signaling. Stimulation of
Ba/F3-MPL cells with TPO or the respective DBs induced dif-
ferent levels of TPO-R receptor phosphorylation, with AK119
comparable to TPO, AK113 slightly less than AK119, and AK111
being the least active (Fig. 1B). Upon TPO stimulation, TPO-R
is phosphorylated at various tyrosine residues on its intracellular
domain. To better understand the signaling properties of the
different DBs and distinguish between complete and partial ag-
onistic activity, we investigated the levels of receptor phosphor-
ylation in three stable cell lines expressing TPO-R mutants
where Tyr residues (all of which are phosphorylated upon TPO
binding) were replaced with Phe (Y591F, Y625F, and Y630F)
(Fig. 1C). While Y591F has been shown to be a negative regu-
lator of TPO signaling and dispensable for proliferation (34),
Y625F is essential for it. Only the Y625F mutant was seemingly
more phosphorylated by AK119 than by AK113 (both higher
than TPO). In contrast, phosphorylation was disrupted after
AK111 treatment in all mutant cells, suggesting partial agonism.
Similarly, AK113 exhibited partial agonistic activities with a
lesser phospho-TPO-R:TPO-R ratio than TPO or AK119 in
wild-type TPO-R, but less in mutated TPO-R (Fig. 1D). DBs
AK119 and 113 show very similar responses to TPO. Indeed, a
positive response is shown using doses in the nano-micromolar
concentration range, whereas DB AK119 presents a very strong
response within picomolar doses. Response saturation is very
similar between DB AK 119 and TPO while saturation is ob-
served with lower doses for DB AK111 and 113 (Fig. 1E). This
qualitative trend was further confirmed when we studied STAT5
phosphorylation (Fig. 1F) and cell proliferation (Fig. 1G) in-
duced by the three DBs in UT-7 TPO-R cells.
Diabodies Induce Graded Signaling Strengths. TPO not only induces
the activation of STAT5/STAT3/STAT1 but, in addition, it ac-
tivates non-STAT pathways such as the MAPK and PI3K that
further modify TPO-mediated responses (Fig. 1H). Previously we
showed for EPO-R that alterations on the ligand–receptor
binding topology could lead to biased signaling (30), thus we
asked whether the same principle would apply to the TPO-R
system, and whether TPO-R DBs were engaging these pathways
as well. To test this, UT-7 TPO-R cells were stimulated with
saturating concentrations of TPO or the three TPO-R DBs for
the indicated times and the levels of over 133 molecules were
analyzed via phospho-specific antibodies and flow cytometry. We
detected activation of 33 different signaling molecules by TPO
and the DBs (Fig. 1H). These molecules included members of
the STAT family (STAT1, STAT3, and STAT5), MAP kinase
family (MEK, p38), and PI3K family (AKT, RSK1, and RPS6).
In contrast to the generally monotonic reduction in phosphory-
lated signaling proteins by the partial agonists (35), we also
found activation of important self-renewal switch pathways
c-MYC and FOS and survival pathways. This may be a result of
the reduction of certain negative regulators resulting in en-
hanced expression of certain pathways; however, the origins and
physiological relevance is not known. Overall, in agreement with
our previous results, the activities of the three DBs ranged from
2 of 10 | PNAS Cui et al.
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Fig. 1. Diabodies induce different degrees of agonism activity. (A) Levels of TPO-R (MPL) binding in yeast (data are from triplicates mean ± SD) and (B) levels
of MPL phosphorylation promoted by DBs at the indicated dosages in Ba/F3 MPL cells. (C) Study of the level of phosphorylation promoted by different DBs in
different phospho mutants of MPL. Y625 corresponds to Y626 in the Uniprot sequence system. (D) Ratio between the nonphosphorylated and phosphory-
lated MPL forms induced by different DBs in Ba/F3 MPL mutant cells (D and E). Data are from triplicates mean ± SD, by one-way ANOVA with Dunnett’s
multiple comparisons test: ns, nonsignificant, *P < 0.05, ***P < 0.001; ****P < 0.0001. (E) Response ratio between low dose of TPO with high dose of TPO and
DBs. Data are from triplicates mean ± SD. (F) Phospho-STAT5 dose–response experiments performed in UT-7 TPO-R cells stimulated with TPO or AK111,
AK113, and AK119 for 15 min. Data mean ± SD are from triplicates. (G) UT-7 TPO-R proliferation in response to TPO or the three DBs for 5 d. (Data mean ± SD
are from triplicates). (H) Diabodies induce graded signaling strengths. Bubble plot representation of the signaling pathways activated by TPO and the DBs at
the indicated times in UT-7–TPO-R cells. The size of the bubbles represents the intensity of the signal activated.
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full agonism for AK119 to a broad reduction of phosphorylation,
indicating partial agonism for AK113 and weak agonism for
AK111. Interestingly, not all 33 molecules were activated to the
same extent by the DBs (Fig. 1H). When the activation levels in-
duced by the three DBs after 15 min of stimulation were normalized
to those induced by TPO, we observed that while TPO and AK119
produced very similar signaling signatures, AK113 elicited a graded
response, with some of the pathways more affected than others. For
example, AK113 elicited almost full agonism for GSK3B and RPS6
activation but very weak agonism for STAT1 and STAT3 (SI
Appendix, Fig. S2). Overall our combined signaling data further
confirm our previous observations that alterations on the
ligand–receptor binding architecture results in fine tuning of the
signaling outputs delivered by cytokine receptors.
Diabodies Dimerize TPO-R at the Surface of Living Cells. We asked
whether the DB/TPO-R complexes on the cell surface are indeed
homodimers or higher-order species resulting from clustering of
TPO-R dimers. To test this, we employed dual-color single
molecule total internal reflection fluorescence (TIRF) micros-
copy to quantify dimerization of TPO-R by different DBs in the
plasma membrane of living cells. Selective and efficient labeling
of TPO-R extracellularly fused to a nonfluorescent, monomeric
EGFP (mXFP) was achieved via anti-GFP nanobodies conju-
gated with Rho11 and Dy647, respectively (Fig. 2A). TPO-R
dimerization was quantified by colocalization and cotracking
analysis of individual molecules with subdiffractional resolution
as schematically depicted in Fig. 2A (Movie S1 and Fig. 2B). In
the absence of stimulation, no cotrajectories were observed.
Upon addition of TPO or DBs, however, colocomoting TPO-Rs
were clearly discerned, though with different efficiencies (Movies
S1–S3 and Fig. 2 B and C). Relative dimerization levels observed
for different DBs are summarized in Fig. 2D. For DB AK119,
similar yet slightly increased dimerization as compared to TPO
was observed. By contrast, dimerization by DB AK111 and 113
were significantly lower, though above the untreated condition.
Since HeLa cells express low levels of JAK2, we coexpressed
TPO-R with JAK2 fused to mEGFP (JAK2-mEGFP), which
function to increase and stabilize cell-surface levels of TPO-R
(36). In JAK2-mEGFP expressing cells, significantly increased
TPO-R dimerization by DB AK119 was obtained, similarly to
TPO. These higher dimerization levels may be ascribed to pro-
ductive interactions of JAK2 homomers within the receptor
complex. Interestingly, the addition of JAK2-mEGFP did not
significantly increase TPO-R dimerization by DB AK111 and
113. This observation suggests that these DBs may form TPO-R
dimers with a strongly altered geometry that do not allow such
productive interactions between TPO-R-bound JAK2 molecules,
which may explain their altered activity profiles.
Diabodies Decouple the Dual Function of TPO/TPO-R duringMegakaryocyte
Differentiation and Block Oncogenic Signaling through the TPO-R. TPO
plays a central role in the differentiation and maturation of mega-
karyocytes. Thus, we investigated the effects of TPO-R DBs in
megakaryocyte differentiation. UT-7 parental cells develop pheno-
types similar to megakaryocytes with TPO and to erythrocytes with
EPO. To test the effects of DBs in this system, we incubated UT-7
cells with EPO, TPO, or the partial or full agonistic TPO-R DBs for
21 d and then quantified megakaryocytic or erythrocytic differentia-
tion in the cultures. AK113 stimulation resulted in weak up-regula-
tion of megakaryocytic genes and down-regulation of erythroid genes,
a physiologic process required during megakaryocytic differentiation
(SI Appendix, Fig. S3). Next, we analyzed the ability of the three
TPO-R DBs to elicit megakaryocyte differentiation in liquid
culture of freshly isolated human CD34+ hematopoietic stem
cell precursors (HSPCs) from bone marrow cells in compari-
son to TPO. We also isolated megakaryocyte-erythroid pro-
genitors (MEPs) by flow cytometry using the indicated markers
(LIN−CD34+CD38+CD135−CD45RA−) and assessed colony-
forming potential of the three DBs in direct comparison to TPO.
We noticed that partial agonists AK111 and AK113 did not support
effective megakaryocytic differentiation (Fig. 3 A–C) nor colony
formation. Despite DBs AK111 and AK113 producing cells
expressing megakaryocytic markers CD41 and CD42b, both resul-
ted in significantly decreased numbers of polyploid cells in liquid
and semisolid culture conditions and were comparable in their low
megakaryocyte differentiation potential to the low stem cell factor
(SCF) (20 ng/mL) condition. In contrast, the full agonistic DB
AK119 effectively promoted megakaryocytic differentiation and
megakaryocytic colony formation to an even greater extent than
TPO (Fig. 3 A–C). We also noted no significant contribution
of TPO DBs to multipotent progenitors (MPPs: lineage-
CD34+CD38−CD90−CD45RA−), megakaryocyte-erythroid pro-
genitors (MEPs: lineage-CD34+CD38+CD135−CD45RA−),
and granulocyte-macrophage progenitors (GMPs: lineage-
CD34+CD38+CD135+CD45RA+), and erythroid precursors,
each accounting for <10% of cells both in liquid and semisolid
culture conditions (SI Appendix, Figs. S4–S6).
Then, we evaluated the differential effects of DBs on HSC
propagation and megakaryocytic differentiation when treated
with DBs AK111 or 113 or 119 or TPO or low SCF (labeled ∅
control). We FACS purified single-cell HSPCs and MPPs by
their characteristic surface markers (HSC-enriched population:
lineage-CD34+CD38−CD45RA−CD90+, MPPs: lineage-
CD34+CD38−CD45RA−CD90−) (Fig. 3 D and E) at the indi-
cated time points. In addition to the indicated factors, HSPCs
were cultured over 15 d. We discovered that HSPCs cultured
without TPO but treated with AK113 or AK111 (partial TPO
agonistic DBs) consistently preserved phenotypic HSPCs to a
greater extent, 80% and ∼50% after 12 d in culture, respectively,
compared to only ∼10% in conditions treated with TPO or
AK119 (full TPO agonistic DB), and very few in ∅ control
(Fig. 3 E and F). Through colony forming and serial replating
assays, we evaluated the ability of HSPCs to self-renew and form
multipotent colonies in vitro after treatment with TPO or DBs
AK111, AK113, and AK119 and weekly cell replating over four
rounds. Initially, we detected low numbers of CFU-GEMM
(colony forming unit that generates myeloid cells) colonies in
AK111, AK113, and HSPCs treated with low concentrations of
SCF without any additional growth factors or diabodies (∅),
compared to twofold increased GEMM colony numbers in TPO-
treated HSPCs after one round of replating. After four rounds of
replating, however, HSPCs treated with low SCF had low num-
bers of CFU-GEMM colonies, whereas HSCs treated with TPO
or AK119 lost their GEMM colony forming capacity. In a stark
contrast, HSPCs treated with DB AK111 and AK113 dramati-
cally increased the number of CFU-GEMM colonies, demon-
strating DB AK111 and AK113’s ability to enhance HSPC
stemness exhibited by increased serial replating in vitro (Fig. 3G).
In addition to effects on normal HSPCs, we were curious whether
partial agonistic DBs could interfere with oncogenic signaling in ET,
a myeloid neoplasm, and preleukemic condition with deregu-
lated TPO signaling. Therefore we investigated whether antag-
onizing TPO signaling would have any therapeutic impact for
ET. We assessed ex vivo colony formation from bone marrow
samples of patients with ET carrying the MPLW515L or the
JAK2V617F mutations. The bone marrow samples were grown
without added cytokines or treated with the AK111 DB. We
discovered that the AK111 DB not only significantly reduced
colony formation in patients with MPLW515L and JAK2V617F
mutated ET but also blocked differentiation toward megakar-
yocytes and platelets (Fig. 3 H and I).
Partial Agonistic Diabodies Propagate Hematopoietic Stem Cells In
Vitro with Distinct Properties. To get a better understanding of
the differential effects of diabodies on gene expression in HSPCs
4 of 10 | PNAS Cui et al.
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Fig. 2. Diabodies dimerize TPO receptor at the surface of living cells. (A) Cell-surface labeling of TPO-R fused to a nonfluorescent mEGFP (mXFP) using dye-
labeled (Rho11 and Dy647) anti-GFP nanobodies (NBs). Coexpression of JAK2-mEGFP can be identified at the single-cell level. Dimerization by TPO (I) and by
DBs (II) is quantified by dual-color single-molecule cotracking as schematically depicted on the Right. (B) Representative trajectories (from 150 frames acquired
in 4.8 s) of individual RHO11-labeled (red) and DY647-labeled (blue) TPO-R and cotrajectories (magenta) observed in a TPO-stimulated cell (cell boundaries are
outlined by a dashed line). (Scale bar, 5 μm.) (C) Trajectories and cotrajectories observed in unstimulated cells and TPO-, AK119-, AK113-, and AK111-treated
conditions. (Scale bars, 5 μm.) (D) Changes in TPO- and DB-induced TPO-R dimerization upon coexpression of JAK2-mEGFP. Each data point represents the
relative number of cotrajectories observed in individual cells. Data are expressed as mean ± SD and analyzed by ordinary one-way ANOVA, ****P < 0.0001; ns,
nonsignificant.
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Fig. 3. Diabodies split the dual function of TPO/TPO-R and block oncogenic signaling in essential thrombocytosis. (A) Percentage of megakaryocytes in CD34+
cells were quantified over 15 d in culture. Immune phenotypic characterization of liquid cultures of human HSCs (HSCs were sorted as Lin-
CD34+CD45RA−CD90+CD38− cells on day 0) on indicated days plated under megakaryocytic differentiation-inducing conditions with indicated cytokines or
DBs (Ø: 20 ng/mL SCF was added to all conditions). Data are expressed as mean ± SD and analyzed by ordinary two-way ANOVA, *P < 0.05, **P < 0.01, ***P <
0.001, ****P < 0.0001; ns, nonsignificant. (B) Quantification of MEP-derived colonies in MegaCult cultures demonstrated minimal megakaryocytic differ-
entiation with SCF and partial agonistic DBs AK111 and AK113, and full megakaryocytic differentiation with TPO and full agonistic DB AK119. Data are
expressed as mean ± SD and analyzed by ordinary one-way ANOVA, ****P < 0.0001; ns, nonsignificant. (C) Representative confocal images of MegaCult
cultures treated with indicated DBs for 15 d, stained for megakaryocytic markers CD41 (red), and nuclear counterstained with DAPI (blue). (Scale bar, 100 μm.)
(D) Gating strategy for HSC isolation from human donor bone marrow (Live+/Lin−/CD34+/CD45RA−/CD90+/CD38−). (E) We measured the percent decrease of
HSCs at the indicated time points after treatment with Ø, AK111, AK113, AK119, or TPO over 15 d. We performed statistical analysis with one-way ANOVA
followed by Dunnett’s multiple comparisons test with Ø as control group. *P < 0.05; **P < 0.01; ****P < 0.0001; ns, nonsignificant. (F) Percent of HSCs under
Ø, AK111, AK113, AK119, and TPO induced culture on day 12. Data are expressed as mean ± SD and analyzed by one-way ANOVA, ****P < 0.0001; ns,
nonsignificant. (G) HSCs are harvested and treated for 12 d in liquid culture with the indicated cytokines or partial agonistic DB AK111, AK113, or AK119 were
subsequently placed in semisolid methylcellulose culture to evaluate their colony forming capacities over four rounds of weekly replating. Quantification of
total numbers of CFU-GEMM colonies at the first and fourth replating for HSCs previously treated with baseline SCF, AK111, AK113, AK119, and TPO in liquid
cultures. Data are shown as mean ± SD. Unpaired t test (**P < 0.01, ***P < 0.001, ****P < 0.0001; ns, nonsignificant). (H) Representative confocal images of
collagen-based cultures of MPLW515L mutated bone marrow of patients with essential thrombocythemia immune stained for CD41 (red) and DAPI (blue).
(Scale bar, 100 μm). (I) Quantification of collagen-based culture assays of MPLW515L and JAK2V617F mutated bone marrow of patients with essential
thrombocythemia treated with indicated DB or without (NoTx). Data are shown as mean ± SD, statistical differences assessed by paired Student’s t test (*P <
0.05. **P < 0.01, ***P < 0.001, ****P < 0.0001).
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propagated in culture, we performed single-cell RNA sequencing
(scRNA-seq) of HSPCs treated with the DBs which we directly
compared to native (=uncultured) HSPCs and MPPs (Fig. 4A).
HSPCs are defined as a quiescent stem cell population and
maintain only low levels of the cell cycle gene TP53 (37). We
confirmed extremely low expression levels of TP53 in native
uncultured human HSPCs. We observed that HSPCs treated
with DB AK111 or AK113 had TP53 levels even lower than
native HSPCs. In contrast, HSPCs cultured solely with TPO or
the full TPO agonistic DB AK119 had much higher expression
levels of TP53 (Fig. 4A). We also quantified proliferation by
nuclear expression of MKI67 and found that HSPCs treated with
AK111 and AK113 did not proliferate, indicated by their low
MKI67 which was similar to native HSPCs, while HSPCs treated
with TPO or AK119 had a much higher MKI67, consistent with
their active cell proliferation. Compared to native HSPCs,
HSPCs cultured with AK111 and AK113 demonstrated similarly
low MKI67 expression (Fig. 4A). This was also the case for BAX,
an apoptosis regulatory gene; native HSPCs and MPPs were
similar to AK111 and AK113 in their low BAX expression, which
was somewhat higher in HSPCs propagated with TPO or AK119.
Uniform manifold approximation and projection (UMAP)
analysis of scRNA-seq data of cultured HSPCs revealed 10
subclusters among which three larger groups are discernable.
Quite interestingly these data demonstrated that the full ago-
nistic diabody AK119 clustered closely with TPO, while the
partial agonistic diabody AK113 clustered in two distinct areas:
one area next to TPO and SCF and another area far apart next to
AK111. AK111 clustered in a spatially distinct area distant from
TPO and AK119 (Fig. 4B). These data support that the different
diabodies induce distinct fate decisions in HSPCs.
Next we studied the change in gene expression profile along
the differentiation path of HSPCs to megakaryocytes in response
to the treatment with different DBs compared to TPO (Fig. 4C
and SI Appendix, Figs. S7 and S8). Quite comparable to TPO,
AK119 activated transcriptional programs in primary HSPCs
across the megakaryocyte differentiation spectrum, including
GATA1, GATA2, and LMO2, transcriptional programs char-
acteristic for MEP stage, as well as programs pertinent for
megakaryocyte precursors and platelets, TAL1, MYBL2, VWF,
and HBD while inhibiting transcription factors driving myeloid
and erythroid differentiation, CEBPA, KIT, ANK1, and EPOR.
These data are in line with our findings described in Fig. 1, which
support that AK119 is a potent and full TPO agonist. Quite in
contrast, AK111 appeared to dampen transcriptional activity
throughout, only allowing for minimal expression of GATAs 1, 2,
and selected myeloid transcriptional programs CEBPA and
SPI1. Quite interestingly, AK113 appeared to suppress MPL
expression in primary cells the most and in a similar manner to
that of native uncultured HSCs, which is in line with data we
showed earlier demonstrating that it was also the most potent in
preserving the undifferentiated stage. In addition, AK113 sup-
pressed megakaryocytic differentiation factors GATA 1 and 2 to
a lesser degree while simultaneously allowing for expression of
myeloid instructive programs KIT and SPI1 (Fig. 4C and SI
Appendix, Figs. S7 and S8). One common feature of all TPO
diabodies was the suppression of erythroid differentiation pro-
grams (e.g., ANK1, EPOR, and ZFPM1 were not expressed),
which was quite similar to that of native uncultured HSPCs and
MPPs. Thus, the partial agonist DBs show a surprising hetero-
geneity in induction of gene expression programs which could, in
principle, lead to different functional effects.
Partial Agonistic Diabodies Act by Reducing Signal Strength through
the TPO/TPO-R. We performed cell clustering of scRNA-seq gene
expression data and distinguished three populations labeled as 1,
2, and 3 (Fig. 4D and SI Appendix, Fig. S9). Based on their single-
cell RNA-seq expression profile, myeloid corresponded to cluster 1,
HSPCs to cluster 2, and megakaryocytic and lineage+ to cluster 3.We
evaluated the frequencies of these three cell populations treated with
partial agonistic DBs in the presence or absence of a TPO-blocking
antibody with single-cell RNA sequencing and compared the results
to cells treated with SCF or TPO. HSC cultures treated with TPO
contained a high percentage of cluster 3, lineage+ megakaryocytic
cells, which decreased significantly with TPO blocking antibody. As
expected, SCF mostly supported myeloid differentiation (cluster 1),
while the cells treated with DB AK119 were quite similar to TPO
supporting megakaryocytic differentiation (cluster 3). However, un-
like TPO, a significant HSPC proportion (cluster 2) was maintained.
In general, HSPCs treated with TPO-blocking antibody demonstrated
a higher percentage of stem cells (cluster 2) and a lower percentage
of megakaryocytic differentiated cells (cluster 3) compared to TPO
(which showed the opposite). We observed a similar trend in HSPCs
treated with DBAK111 and to a lesser extent with DBAK113, which
retains a higher level of signaling activity (SI Appendix, Fig. S7).
UMAP plots in Fig. 4D demonstrate that treatment with DBs AK111
and with AK113 in a subset of cells appeared to have similar effects
to the TPO-blocking antibody on HSPCs after 15 d of in vitro culture.
Thus these data suggest that HSPC maintenance/expansion by DBs
AK111 and 113 is achieved by inverse agonism of TPO. Collectively
these data demonstrate that partially agonizing TPO with DBs can
fine tune the switch between HSPC self-renewal and megakar-
yocytic differentiation and counteract oncogenic signaling in
MPL and JAK2 mutated ET (Fig. 4E).
Discussion
Here we have explored the effects of manipulating TPO-R sig-
naling in hematopoietic-fate decisions using surrogate TPO ag-
onists and partial agonistic DBs. We have created a collection of
TPO surrogate ligands with graded signaling potencies and
strengths, enabling us to study this parameter on HSPC biology.
While all three DBs bound with comparable affinities to TPO-R,
their downstream signaling outputs greatly differed and deter-
mined cell fate—maintenance of an HSPC-like state with DBs
AK111 and AK113 versus full maturation to megakaryocytes
with AK119. While the structural basis of the differing signaling
outputs elicited by the DBs is not resolved here, most likely the
DBs bind to different epitopes on the TPO-R, resulting in a
different range of dimeric TPO-R orientations and proximities.
However, we cannot exclude that other mechanisms are at play,
such as that diabodies induce different levels of internalization,
degradation/recycling of the TPO-R, which could also influence
the signaling properties. This is conceptually consistent with a pre-
vious study on DBs to EPO-R that elicited a similar pharmacological
profile of full to partial agonism (30, 38). Structural analysis of the
DB/EPO-R complexes revealed strikingly different EPO-R dimer-
ization topologies that presumably impacted the orientation of the
intracellular signaling machinery. Here we have extended this con-
cept about basic mechanisms of cytokine–receptor signaling, to
applications in HSPC biology with therapeutic implications. This
study, along with others demonstrating the effects of cytokine
partial agonism on cytokine pleiotropy and function in systems
such as IL-2, interferons, and stem cell factor, show protein
engineering can generate partial agonists with unique pharma-
cology for dimeric receptors, borrowing conceptually from the
GPCR structure–activity approaches, with distinctive functional
properties that can be advantageous over wild type (39–41).
Allogeneic HSC transplant is the only curative therapy for
numerous hematologic malignancies and autoimmune diseases.
While human HSPCs have been successfully purified since the
1980s, their small cell numbers have limited their use in human
transplant protocols. Purified HSPC grafts would offer many
advantages over CD34+-enriched stem cell grafts. For example,
purified HSC grafts do not confer acute and chronic graft versus
host disease (cGVHD), which is the leading cause of mortality
and morbidity following a bone marrow transplant.
Cui et al. PNAS | 7 of 10




































































































































































































































































































































































































































































































































































































































































Fig. 4. Partial agonistic diabodies propagate HSCs in vitro with distinct properties. (A) scRNA-seq analysis shows the expression profiles of TP53, MKI67, and
BAX (cell proliferation markers) in HSCs after 12-d culture with Ø (20 ng/mL SCF) and combined with TPO DBs or TPO (100 nM). (B) UMAP plots showing
scRNA-seq data of FACS-isolated human HSCs (CD34+CD45RA−CD90+CD38−) of five different culture conditions: Ø (20 ng/mL SCF) and combined with TPO DBs
or TPO (100 nM). (C) Violin plots showing expression levels of genes critical for hematopoietic differentiation from HSC, MPP, MEP, MKP, platelet, mature
myeloid, and erythroid lineage stages for all diabody conditions on day 12 in culture. (D) UMAP plots showing scRNA-seq data of FACS-isolated human HSCs
(CD34+CD45RA−CD90+CD38−) after treatment with blocking antibodies against TPO (R&D, AF-288-NA). (E) Graphical schemata showing effects of diabodies
on HSC proliferation and megakaryocytic differentiation.
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Despite substantial efforts to identify factors in the microen-
vironment of the bone marrow to support HSC stemness (2, 3, 6,
7), it has not as yet been possible to stably expand purified hu-
man HSPCs ex vivo for clinical use despite preclinical work
demonstrating that HSCs can be propagated in culture with
polyvinyl alcohol (PVA) scaffold, pyrimidoindole-derived mole-
cules, HOXB, or by suppressing the aryl hydrocarbon receptor
(16, 42–44). In this study we demonstrated that partial agonistic
DBs AK111 and AK113 allow for HSPC maintenance and ex-
pansion ex vivo by diminishing and/or modulating activating
downstream signals through TPO-R. In contrast to these other
approaches which act through obscure mechanisms, TPO DBs
modulate signaling solely through the TPO-R; thus side effects
are anticipated to be minimal. TPO-DBs are able to deliver
customized intensities of downstream TPO-R signals, and thus
mimic the physiological conditions of the TPO regulation while
more tightly controlling downstream signaling output. In addi-
tion, the TPO DBs split the functions of TPO with regard to
megakaryopoiesis and HSPC expansion, a unique feature, which
is not a property of any of the available TPO mimetics nor the
above-mentioned stem cell expanding experimental reagents.
The dual function of TPO is an unanswered and burning open
question in the otherwise well-studied field of TPO signaling.
Thus, TPO DBs also represent an interesting reagent for further
exploratory research in this area.
The importance of cytokines in maintaining the HSPC pool
and cell lineage specifications has been well established in the
literature. For instance, SCF and TPO are required cytokines for
HSPCs. While HSPCs generated by DBs show strong gene ex-
pression similarities with uncultured HSPCs by single-cell RNA-
seq, they also have very specific features. HSCAK111 expressed
increased IL6R and decreased FLT3 ligand compared to un-
cultured HSPCs. It is understood that the expression of FLT3
increases between the HSPC and MPP stage and plays a key role
for multipotent and lymphoid progenitors and myeloid cells.
While the absence of FLT3L does not alter megakaryocyte–
erythroid progenitor development, the cytokine TPO has been
shown to potentiate FLT3-mediated effects. Our single-cell
RNA-seq data show that HSPCs cultured with partial agonistic
TPO DBs lacked FLT3 expression and retained at least short-
term stem cell-like properties; thus, these culture conditions
appear optimal for stem cell maintenance.
Using single-cell transcriptomics (scRNA-seq) in conjunction
with protein expression studies, we confirmed that the stem cells
generated by DBs produce an original pool of stem cells in vitro
(45, 46). By clustering HSPCs and MPPs we can conclude that
after nearly 2 wk of culture, the HSCAK111 populations are closer
to HSPC than MPP populations. For example, the HSCAK111
populations demonstrate a TP53 expression pattern very similar
to that of uncultured HSPCs. We know that TP53 expression is
tightly controlled in HSPCs, and it has been shown that the
Trp53, p16, p19 triple mutant allows long-term hematopoietic
reconstitution (47) and HSPC expansion (48). Our studies show
a basal low level of TP53 in HSC AK111 quite similar to HSCs.
More recently, it has been demonstrated that mutations in the
cytokine TPO reduce engraftment capacity, further demon-
strating the essential role of TPO for primary hematopoiesis (42,
49). The use of TPO as a drug initially had been quite limited
due to antibody formation and thrombocytopenia. Nevertheless,
the second generation of TPO receptor agonists are now being
used successfully in the clinic for severe immune thrombocyto-
penias and bone marrow failure syndromes and are under eval-
uation for a wide range of other thrombocytopenic disorders,
including those associated with chemotherapy and myelodys-
plastic syndromes. Thus, while generally much better tolerated,
unwanted side effects still occur with second generation TPO
mimetics, including thrombocytosis, thrombosis, bone marrow
reticulin fibrosis, rebound thrombocytopenia, and liver toxicity.
DBs deliver different intensities of downstream MPL signals,
and thus mimic the physiological conditions of TPO regulation
while more tightly controlling downstream signaling output. In
addition to the above-discussed applications, we found this to be
particularly relevant to oncogenic signaling downstream of the
TPO-R as they occur in ET, a myeloproliferative neoplasm. To
our great surprise we discovered that partial agonistic TPO DB
blocked oncogenic colony formation in patients with ET by
partially agonizing downstream signaling of TPO-R. Potential
clinical applications of TPO DB could be conditions requiring
full or partial TPO agonism such as platelet production, HSC
expansion/maintenance, as well as oncogenic signaling in ET.
Materials and Methods
Details of the experimental protocols can be found in SI Appendix, Sup-
plementary Materials and Methods.
TPO-R Diabodies Binding Experiments. The Saccharomyces cerevisiae strain
EBY100 was transformed with the pCT302_TPO-R SD1-2 vector and grown
for 2 d at 30 °C on selective dextrose casamino acids (SDCAA) media, fol-
lowed by induction in selective galactose casamino acids (SGCAA) media (pH
4.5) for 2 d at 20 °C. Yeast were then incubated with the indicated con-
centrations of biotinylated TPO-R diabodies for 1 h at 4 °C, followed by
streptavidin-Alexa 647 (1:200 dilution) for 15 min at 4 °C. Fluorescence was
analyzed on an Accuri C6 flow cytometer.
Statistics. Statistical analyses were performed using Prism software (Graph-
Pad Software). Statistical significance was determined by the unpaired Stu-
dent’s t test for comparisons between two groups and one-way ANOVA for
multigroup comparisons (ns, nonsignificant; P > 0.05; *P < 0.05; **P < 0.01;
***P < 0.001; ****P < 0.0001). In statistical graphs, points indicate individual
samples, and results represent the mean ± SD unless indicated otherwise.
Study Approval. Healthy deidentified human bone marrow samples were
acquired from AllCells. Essential thrombocytosis bone marrow samples were
deidentified and acquired from the Stanford University Medical Center
through Jason Gotlib, according to Institutional Review Board (IRB)-approved
protocol 18329 or as discard samples from the Pathology Department under
IRB 39881. Mice were maintained in the Stanford University Laboratory
Animal Facility in accordance with Stanford Animal Care and Use Committee
and National Institutes of Health guidelines (SU-APLAC 30912).
Data Availability. scRNA sequencing data have been deposited in the Gene
Expression Omnibus (GEO) at the National Center for Biotechnology Infor-
mation (NCBI) under accession GSE115235. All the data are included in the
main text and supporting information.
ACKNOWLEDGMENTS. K.C.G. acknowledges NIH-RO1-AI51321, the Ludwig
Institute, the Mathers Foundation, and HHMI for funding; G.W. acknowl-
edges the National Heart, Lung, and Blood Institute, the Ludwig Institute,
Scleroderma Research Foundation (SRF), and the Emmerson Collective.
Deutsche Forschungsgesellschaft (DFG) provided salary support to T.L. and
I.S.H. was supported by Cancer Research UK grant A24593 and by the
University of York Technology Facility.
1. S. Lok et al., Cloning and expression of murine thrombopoietin cDNA and stimulation
of platelet production in vivo. Nature 369, 565–568 (1994).
2. F. Wendling et al., cMpl ligand is a humoral regulator of megakaryocytopoiesis. Na-
ture 369, 571–574 (1994).
3. F. J. de Sauvage et al., Stimulation of megakaryocytopoiesis and thrombopoiesis by
the c-Mpl ligand. Nature 369, 533–538 (1994).
4. K. Kaushansky et al., Promotion of megakaryocyte progenitor expansion and differ-
entiation by the c-Mpl ligand thrombopoietin. Nature 369, 568–571 (1994).
5. I. Vigon et al., Molecular cloning and characterization of MPL, the human homolog of
the v-mpl oncogene: Identification of a member of the hematopoietic growth factor
receptor superfamily. Proc. Natl. Acad. Sci. U.S.A. 89, 5640–5644 (1992).
6. I. Vigon et al., Characterization of the murine Mpl proto-oncogene, a member of the
hematopoietic cytokine receptor family: Molecular cloning, chromosomal location
and evidence for a function in cell growth. Oncogene 8, 2607–2615 (1993).
7. R. C. Skoda et al., Murine c-mpl: A member of the hematopoietic growth factor re-
ceptor superfamily that transduces a proliferative signal. EMBO J. 12, 2645–2653 (1993).
Cui et al. PNAS | 9 of 10

































8. A. L. Gurney, K. Carver-Moore, F. J. de Sauvage, M. W. Moore, Thrombocytopenia in
c-mpl-deficient mice. Science 265, 1445–1447 (1994).
9. F. J. de Sauvage et al., Physiological regulation of early and late stages of mega-
karyocytopoiesis by thrombopoietin. J. Exp. Med. 183, 651–656 (1996).
10. H. Yoshihara et al., Thrombopoietin/MPL signaling regulates hematopoietic stem cell
quiescence and interact\ion with the osteoblastic niche. Cell Stem Cell 1, 685–697
(2007).
11. H. Qian et al., Critical role of thrombopoietin in maintaining adult quiescent hema-
topoietic stem cells. Cell Stem Cell 1, 671–684 (2007).
12. S. Kimura, A. W. Roberts, D. Metcalf, W. S. Alexander, Hematopoietic stem cell de-
ficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. Proc. Natl. Acad. Sci.
U.S.A. 95, 1195–1200 (1998).
13. G. P. Solar et al., Role of c-mpl in early hematopoiesis. Blood 92, 4–10 (1998).
14. K. Carver-Moore et al., Low levels of erythroid and myeloid progenitors in throm-
bopoietin-and c-mpl-deficient mice. Blood 88, 803–808 (1996).
15. N. Fox, G. Priestley, T. Papayannopoulou, K. Kaushansky, Thrombopoietin expands
hematopoietic stem cells after transplantation. J. Clin. Invest. 110, 389–394 (2002).
16. A. C. Wilkinson et al., Long-term ex vivo haematopoietic-stem-cell expansion allows
nonconditioned transplantation. Nature 571, 117–121 (2019).
17. Y. Pikman et al., MPLW515L is a novel somatic activating mutation in myelofibrosis
with myeloid metaplasia. PLoS Med. 3, e270 (2006).
18. A. D. Pardanani et al., MPL515 mutations in myeloproliferative and other myeloid
disorders: A study of 1182 patients. Blood 108, 3472–3476 (2006).
19. M. Ballmaier et al., c-mpl mutations are the cause of congenital amegakaryocytic
thrombocytopenia. Blood 97, 139–146 (2001).
20. A. Pecci et al., Thrombopoietin mutation in congenital amegakaryocytic thrombo-
cytopenia treatable with romiplostim. EMBO Mol. Med. 10, 63–75 (2018).
21. D. M. Townsley et al., Eltrombopag added to standard immunosuppression for
aplastic anemia. N. Engl. J. Med. 376, 1540–1550 (2017).
22. D. J. Kuter, Clinical applications of thrombopoietic growth factors. https://www.up-
todate.com/contents/clinical-applications-of-thrombopoietic-growth-factors. Accessed 4
January 2018.
23. J. B. Bussel et al., Eltrombopag for the treatment of chronic idiopathic thrombocy-
topenic purpura. N. Engl. J. Med. 357, 2237–2247 (2007).
24. W. Vainchenker, I. Plo, C. Marty, L. N. Varghese, S. N. Constantinescu, The role of the
thrombopoietin receptor MPL in myeloproliferative neoplasms: Recent findings and
potential therapeutic applications. Expert Rev. Hematol. 12, 437–448 (2019).
25. L. N. Varghese, J. P. Defour, C. Pecquet, S. N. Constantinescu, The thrombopoietin
receptor: Structural basis of traffic and activation by ligand, mutations, agonists, and
mutated calreticulin. Front. Endocrinol. (Lausanne) 8, 59 (2017).
26. S. Wilmes et al., Mechanism of homodimeric cytokine receptor activation and dys-
regulation by oncogenic mutations. Science 367, 643–652 (2020).
27. J. Staerk et al., Orientation-specific signalling by thrombopoietin receptor dimers.
EMBO J. 30, 4398–4413 (2011).
28. J. Li et al., Thrombocytopenia caused by the development of antibodies to throm-
bopoietin. Blood 98, 3241–3248 (2001).
29. K. Nakano et al., Effective screening method of agonistic diabodies based on auto-
crine growth. J. Immunol. Methods 347, 31–35 (2009).
30. I. Moraga et al., Tuning cytokine receptor signaling by re-orienting dimer geometry
with surrogate ligands. Cell 160, 1196–1208 (2015).
31. C. Gawad, W. Koh, S. R. Quake, Single-cell genome sequencing: Current state of the
science. Nat. Rev. Genet. 17, 175–188 (2016).
32. Tarashansky A. J., Yuan X., S. R. Quake, B. Wang, Self-assembling manifolds in single-
cell RNA sequencing data. Elife 8, e48994 (2018).
33. S. Nikiforow, J. Ritz, Dramatic expansion of HSCs: New possibilities for HSC trans-
plants? Cell Stem Cell 18, 10–12 (2016).
34. V. Sangkhae, S. J. Saur, A. Kaushansky, K. Kaushansky, I. S. Hitchcock, Phosphorylated
c-Mpl tyrosine 591 regulates thrombopoietin-induced signaling. Exp Hematol. 42,
477–486.e4 (2014).
35. G. A. Millot, W. Vainchenker, D. Duménil, F. Svinarchuk, Distinct effects of throm-
bopoietin depending on a threshold level of activated Mpl in BaF-3 cells. J. Cell Sci.
115, 2329–2337 (2002).
36. Y. Royer, J. Staerk, M. Costuleanu, P. J. Courtoy, S. N. Constantinescu, Janus kinases
affect thrombopoietin receptor cell surface localization and stability. J. Biol. Chem.
280, 27251–27261 (2005).
37. L. Papa et al., Ex vivo human HSC expansion requires coordination of cellular re-
programming with mitochondrial remodeling and p53 activation. Blood Adv. 2,
2766–2779 (2018).
38. K. Mohan et al., Topological control of cytokine receptor signaling induces differ-
ential effects in hematopoiesis. Science 364, eaav7532 (2019).
39. J. L. Mendoza et al., Structure of the IFNγ receptor complex guides design of biased
agonists. Nature 567, 56–60 (2019).
40. S. Mitra et al., Interleukin-2 activity can be fine tuned with engineered receptor
signaling clamps. Immunity 42, 826–838 (2015).
41. C. C. M. Ho et al., Decoupling the functional pleiotropy of stem cell factor by tuning
c-kit signaling. Cell 168, 1041–1052.e18 (2017).
42. S. Kohlscheen, F. Schenk, M. G. E. Rommel, K. Cullmann, U. Modlich, Endothelial
protein C receptor supports hematopoietic stem cell engraftment and expansion in
Mpl-deficient mice. Blood 133, 1465–1478 (2019).
43. I. Fares et al., Pyrimidoindole derivatives are agonists of humanhematopoietic stem
cell self-renewal. Science, 10.1126/science.1256337 (2014).
44. E. Csaszar, Rapid expansion of human hematopoietic stem cells by automated control
of inhibitory feedback signaling. Cell Stem Cell, 10.1016/j.stem.2012.01.003 (2012).
45. S. Nestorowa et al., A single-cell resolution map of mouse hematopoietic stem and
progenitor cell differentiation. Blood 128, e20–e31 (2016).
46. X. T. Huang et al., Technical advances in single-cell RNA sequencing and applications
in normal and malignant hematopoiesis. Front. Oncol. 8, 582 (2018).
47. O. O. Akala et al., Long-term haematopoietic reconstitution by Trp53-/-p16Ink4a-/-
p19Arf-/- multipotent progenitors. Nature 453, 228–232 (2008).
48. M. TeKippe, D. E. Harrison, J. Chen, Expansion of hematopoietic stem cell phenotype
and activity in Trp53-null mice. Exp. Hematol. 31, 521–527 (2003).
49. A. Seo et al., Bone marrow failure unresponsive to bone marrow transplant is caused
by mutations in thrombopoietin. Blood 130, 875–880 (2017).
10 of 10 | PNAS Cui et al.
https://doi.org/10.1073/pnas.2017849118 Tuning MPL signaling to influence hematopoietic stem cell differentiation and inhibit
essential thrombocythemia progenitors
D
ow
nl
oa
de
d 
by
 g
ue
st
 o
n 
Ja
nu
ar
y 
12
, 2
02
1 
